GlobeNewswire by notified

Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing composition.


31 October 2023

Announcement no. 41

Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing composition.

Reponex Pharmaceuticals A/S (Reponex) today announced that the United States Patent and Trademark Office (USPTO) s approved the US patent application 16/366.898. This application describes a method of treating a chronic wound by the topical application of a hydrogel containing granulocyte-macrophage colony-stimulating factor (GM-CSF), sucralfate and hyaluronan to accelerate wound healing.

“Reponex’s treatment combines three active substances that accelerates the healing of chronic wounds such as venous and diabetic leg ulcers. We are pleased that the USPTO have now approved our patent application for our treatment method, the USA being such an important commercial area,” says Thomas Kaas Selsø, CEO of Pharma Equity Group A/S.

According to Grand View Research, the global wound care market size was valued at USD 21.4 billion in 2022 and is expected to grow at a compound annual rate (CAGR) of 4.15% from 2023 to 2030. Of this, the market in the USA accounts for approx. USD 8 billion in 2022. The chronic wounds segment held the largest share of approx. 60% in 2022.

The patent is valid until 2039.

For further information, please contact

Thomas Kaas Selsø, CEO
Telephone: +45 4022 2114

About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group: periodic report on the buyback program11.12.2023 17:50:00 CET | Press release

Turin, 11th December 2023. Iveco Group N.V. (EXM: IVG) announces that, under the ongoing initial tranche of the common share buyback program announced on 14th April 2023, the Company completed on a daily basis, starting from 4th December 2023 to 8th December 2023 the following transactions: DateNumber of repurchased Common SharesAverage net price (euro)Total net consideration (euro)4 December 202336,0007.6118274,025.345 December 202336,0007.7060277,414.386 December 202335,0007.8616275,157.067 December 202334,5007.9324273,666.398 December 202335,2007.9369279,378.57Total176,7007.80781,379,641.73 An overall overview of the purchases carried out under the current share buyback program as well as the details of the above transactions, are available on the Company’s corporate website at the following address: Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance

Stämmokommuniké från extra bolagsstämma den 11 december 2023 i Anoto Group AB (publ) samt utseende av ny VD11.12.2023 17:45:00 CET | Pressemelding

Anoto Group AB (publ) (”Bolaget”) har den 11 december 2023 hållit extra bolagsstämma där i huvudsak följande beslut fattades. Styrelse Bolagsstämman beslutade att styrelsen för tiden intill slutet av nästa årsstämma skulle bestå av Dennis Song, Injoon Jeong, Pedro Pinto och Hans Haywood. Bolagsstämman valde Dennis Song till styrelseordförande. Styrelsearvode Bolagsstämman beslutade att ersättning till styrelsen ska utgå enligt årsstämmans beslut (dvs. 900 000 kronor till styrelsens ordförande och 300 000 kronor till var och en av övriga ordinarie styrelseledamöter som inte är anställda i koncernen att reduceras proportionellt med hänsyn till att den nya styrelsen inte kommer att tjänstgöra under hela perioden mellan årsstämman den 30 juni 2023 och nästa årsstämma). Bemyndigande för styrelsen att besluta om nyemission av stamaktier, emission av teckningsoptioner och/eller konvertibler Stämman beslutade att bemyndiga styrelsen att längst intill nästa årsstämma, vid ett eller flera tillfä

Bulletin from the Extraordinary General Meeting in Anoto Group AB (publ) on 11 December 2023, and appointment of new CEO11.12.2023 17:45:00 CET | Press release

The Extra General Meeting (the “EGM”) in Anoto Group AB (publ) (the “Company”) has been held on 11 December 2023 and in particular the following decisions were resolved. The Board The EGM decided that the Board of Directors for the period until the end of the next AGM shall consist of Dennis Song, Injoon Jeong, Pedro Pinto and Hans Haywood. The EGM elected Dennis Song as the Chairman of the Board of Directors. Remuneration for the Board of Directors The EGM resolved that the remuneration to the Board of Directors shall be paid in accordance with the resolution of the AGM (i.e. SEK 900,000 to the Chairman of the Board of Directors and SEK 300,000 to each of the other ordinary members of the Board of Directors who are not employed by the group to be reduced proportionally taking into account that the new Board of Directors will not serve for the entire period between the AGM on 30 June 2023 and the next AGM). Resolution to authorise the Board of Directors to issue new ordinary shares, wa

Innofactor Plc: Share Repurchase 11.12.202311.12.2023 17:30:00 CET | Press release

Innofactor Plc Announcement 11.12.2023Innofactor Plc: Share Repurchase 11.12.2023In the Helsinki Stock ExchangeTrade date 11.12.2023Bourse trade BuyShare IFA1VAmount 4,300SharesAverage price/ share 1.1599EURTotal cost 4,987.57EURInnofactor Plc now holds a total of 584 329 sharesincluding the shares repurchased on 11.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 Attachment Innofactor_11.12_trades

Mandatory notification of trade and acceptance by primary insiders11.12.2023 17:12:12 CET | Press release

Reference is made to the stock exchange announcement on 7 December 2023 whereby BW Sirocco Holdings AS (the "Offeror") announced the completion and settlement of the Offer and the acquisition of the Offeror of 30,000,561 shares, representing approximately 95.21% of the total number of shares in BW Ideol AS. The Offeror, being a close associate of Marco Beenen, the chairperson of the board of directors of BW Ideol AS, attach the required notifications of trade to this announcement. Further, mandatory notifications from other primary insiders and their related parties are also attached to this announcement. For further information, please contact: BW Ideol AS Nicolas de Kerangal (Chief Financial & Partnerships Officer) +33 (0) 7 76 87 70 08 / ( BW Sirocco Holdings AS Anders S. Platou (Chief Strategy Officer BW Offshore Limited) +47 99 71 86 55 Attachment Project Sirocco - PDMR - Attachments